Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.57 |
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.57 |
| ▸ | CHRM4 known ✓ | P08173 | 4/20 | 0.57 |
| ▸ | CHRM5 known ✓ | P08912 | 4/20 | 0.57 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.57 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.57 |
| ▸ | DRD1 known ✓ | P21728 | 4/20 | 0.57 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 0.57 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.57 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.57 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 0.57 |
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.57 |
| ▸ | ADRA1B known ✓ | P35368 | 4/20 | 0.57 |
| ▸ | HTR2B known ✓ | P41595 | 4/20 | 0.57 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.57 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.57 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.57 |
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.57 |
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.57 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30040103 | 1.00 | DRD2 (0.57) | DRD2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL79367 | 0.99 | DRD2 (0.58) | DRD2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12208493 | 0.84 | DRD2 (0.61) | DRD2CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL4847359 | 0.82 | DRD2 (0.40) | DRD2CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL4841102 | 0.82 | CHRM1 (0.40) | DRD2CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL4846674 | 0.82 | DRD2 (0.40) | DRD2CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL4840025 | 0.82 | DRD1 (0.40) | DRD2CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL4844507 | 0.82 | HTR2A (0.40) | DRD2CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL4839524 | 0.82 | CHRM2 (0.40) | DRD2CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL15485334 | 0.81 | DRD2 (0.42) | DRD2CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014157860-A1 | PROCESS FOR THE PREPARATION OF HIGH PURITY OLANZAPINE AND CRYSTALLINE FORM II THEREOF | DONG-A ST CO., LTD (KR) | 2014-10-02 | — | — | WO | claimed |
| CN-102276592-B | Related substance of olanzapine and preparation method and analytical method thereof | UNIV DALIAN TECH | 2013-10-16 | — | — | CN | claimed |
| CN-102268010-A | Preparation method and refining method of olanzapine | — | 2011-12-07 | — | — | CN | claimed |
| EP-1963335-B1 | PROCESS FOR THE PREPARATION OF OLANZAPINE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKOEDOE RESZVENYTARSASAG (HU) | 2011-05-04 | — | — | EP | claimed |
| EP-1513846-B1 | PROCESS OF PREPARATION OF OLANZAPINE FORM I | SANDOZ AG (CH) | 2011-03-02 | — | — | EP | claimed |
| US-7834176-B2 | Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E | SANDOZ AG (CH) | 2010-11-16 | — | — | US | claimed |
| US-7538213-B2 | Methods for preparation of olanzapine polymorphic form I | INSTITUT FARMACEUTYCZNY (PL) | 2009-05-26 | — | — | US | claimed |
| US-20080161557-A1 | Synthesis of 2-Methyl-4-(4-Methyl-1-Piperazinly)-10H-Thieno(2,3-B) (1,5) Benzodiazepine and Salts Thereof | LEK PHARMACEUTICALS D.D. (SL) | 2008-07-03 | — | — | US | claimed |
| EP-1611139-B1 | METHODS OF PREPARING OLANZAPINE | TEVA PHARMA (IL) | 2008-06-04 | — | — | EP | claimed |
| US-RE40033-E1 | Process for preparing 2-methyl-thieno-benzodiazepine | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | claimed |
| US-20070072845-A1 | Process for the preparation of olanzapine form 1 useful as antipsychotic drug | RAMMOHAN RAO DAVULURI | 2007-03-29 | — | — | US | claimed |
| EP-1749010-A2 | SYNTHESIS OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO 2, 3-B 1,5 BENZODIAZEPINE AND SALTS THEREOF | LEK Pharmaceuticals D.D. (SI) | 2007-02-07 | — | — | EP | claimed |
| US-20050239772-A1 | METHODS FOR PREPARATION OF OLANZAPINE POLYMORPHIC FORM I | INSTITUT FARMACEUTYCZNY (PL) | 2005-10-27 | — | — | US | claimed |
| WO-2005090359-A2 | SYNTHESIS OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2, 3-B][1,5]BENZODIAZEPINE AND SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2005-09-29 | — | — | WO | claimed |
| EP-1513846-A1 | PROCESS OF PREPARATION OF OLANZAPINE FORM I | Sandoz Inc. (US) | 2005-03-16 | — | — | EP | claimed |
| US-20040067936-A1 | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine | REDDY'S LABORATORIES LIMITED (IN) | 2004-04-08 | — | — | US | claimed |
| US-20040048854-A1 | Process of preparation of olanzapine Form I | SANDOZ AG (CH) | 2004-03-11 | — | — | US | claimed |
| WO-2003101997-A1 | PROCESS OF PREPARATION OF OLANZAPINE FORM I | GENEVA PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | claimed |
| EP-1313742-A1 | PROCESS FOR PREPARATION OF HYDRATES OF OLANZAPINE AND THEIR CONVERSION INTO CRYSTALLINE FORMS OF OLANZAPINE | Dr. Reddy's Laboratories Ltd. (IN) | 2003-05-28 | — | — | EP | claimed |
| WO-2002018390-A1 | PROCESS FOR PREPARATION OF HYDRATES OF OLANZAPINE AND THEIR CONVERSION INTO CRYSTALLINE FORMS OF OLANZAPINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2002-03-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048854-A1 | Process of preparation of olanzapine Form I | HTR1B, CYP1B1, HTR1A | DRD2 102/4885CHRM2 220/4885CHRM4 269/4885 |
| US-20080161557-A1 | Synthesis of 2-Methyl-4-(4-Methyl-1-Piperazinly)-10H-Thieno(2,3-B) (1,5) Benzodiazepine and Salts Thereof | GABRA5, HTR3C, GABRA1 | DRD2 17/4885CHRM2 471/4885CHRM4 299/4885 |
| US-20040067936-A1 | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine | CYP2F1, FIS1, CYP4B1 | DRD2 123/4885CHRM2 163/4885CHRM4 207/4885 |
| US-20070072845-A1 | Process for the preparation of olanzapine form 1 useful as antipsychotic drug | HTR1D, HTR3C, CYP3A5 | DRD2 20/4885CHRM2 461/4885CHRM4 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.